Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

More than 1 million babies worldwide born prematurely die in first month, Study says

Each year more than 1 million babies born prematurely - before 37 weeks of development in the womb or within the first month of life - the "March of Dimes said Sunday in the first comprehensive global report on premature births," CNN reports. Nearly 10 percent of total births worldwide, or 12.9 million infants, are preterm, the study found.

6 Oct 2009

FOLOTYN available for commercial sale in the United States

Allos Therapeutics, Inc. today announced that FOLOTYN (pralatrexate injection) is now available for commercial sale in the United States. The U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) on September 24, 2009. This indication is based on overall response rate.

6 Oct 2009

Breast milk should not be stored and fed later

The levels of the components in breast milk change every 24 hours in response to the needs of the baby. A new study published in the journal Nutritional Neuroscience shows, for example, how this milk could help newborn babies to sleep.

3 Oct 2009

Doris Duke Innovations award for sickle cell disease research

Sangamo BioSciences, Inc. announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, has been selected to receive a $486,000 Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation.

1 Oct 2009

Medgenics announces unaudited half-yearly results for the six months ended 30 June 2009

Medgenics (AIM:MEDG) (AIM:MEDU) is pleased to announce its unaudited half-yearly results for the six months ended 30 June 2009.

30 Sep 2009

Ligand and GSK amend agreement to pursue independent research programs

Ligand Pharmaceuticals Incorporated today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline, GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would otherwise have been required upon the identification of a new lead chemical series for advancement in its alliance with GSK.

29 Sep 2009

NECBB reports cord blood banking is on the rise

New England Cord Blood Bank, Inc. (NECBB), a global cord blood processing and storage facility, announced today that the company has seen a consistent and robust increase in the cord blood units being used for transplants within the past few years.

29 Sep 2009

Hookworms can prevent asthma

A study conducted in Vietnam has added further weight to the view that parasitic gut worms, such as hookworm, could help in the prevention and treatment of asthma and other allergies.

29 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

Affymax may sell up to.$60 million of its registered common stock to Azimuth Opportunity

Affymax, Inc. (Nasdaq:AFFY) today announced that it has obtained an issuer managed equity facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity, Ltd. Affymax is not obligated to utilize any of the facility, which has a term of 24 months.

25 Sep 2009

Research to develop small-molecule drug that blocks excess iron absorption

Excess iron in the body, if left unchecked, can form toxic deposits in major organs leading to serious conditions including heart failure, diabetes, liver cirrhosis, arthritis, and even infertility. Iron overload can be a consequence of a genetically mutated gene known as hereditary hemochromatosis, or a consequence of red blood cell transfusions, required as life saving treatments, for patients with diseases such as thalassemia.

25 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Celebrities perform for children's fundraising project

Grammy Award-winning singer-songwriter John Legend and artist/designer Noah G POP joined forces last night at NYC's Nikki Beach Midtown for Project Sunshine's fall fundraiser to benefit children facing medical challenges.

23 Sep 2009

Biotime's new subsidiary to focus on clinical development and marketing therapeutic stem cell products in China

BioTime, Inc. (OTCBB:BTIM) announced today that it will organize a new subsidiary, BioTime Asia, Limited, for the purpose of clinically developing and marketing therapeutic stem cell products in the People’s Republic of China, and marketing stem cell research products in China and other countries in Asia.

23 Sep 2009

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.

22 Sep 2009

Lundbeck offers Sabril for treating children with infantile spasms in the U.S.

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that Sabril® (vigabatrin) Tablets and Powder for Oral Solution are now available for prescribing in the United States.

22 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

Anemia News and Research

Further Reading

More than 1 million babies worldwide born prematurely die in first month, Study says

FOLOTYN available for commercial sale in the United States

Breast milk should not be stored and fed later

Doris Duke Innovations award for sickle cell disease research

Medgenics announces unaudited half-yearly results for the six months ended 30 June 2009

Ligand and GSK amend agreement to pursue independent research programs

NECBB reports cord blood banking is on the rise

Hookworms can prevent asthma

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Affymax may sell up to.$60 million of its registered common stock to Azimuth Opportunity

Research to develop small-molecule drug that blocks excess iron absorption

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Celebrities perform for children's fundraising project

Biotime's new subsidiary to focus on clinical development and marketing therapeutic stem cell products in China

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

Lundbeck offers Sabril for treating children with infantile spasms in the U.S.

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Millennium's sNDA for VELCADE granted priority review by the FDA

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News